目的

探讨核苷酸切除修复基因家族成员ERCC1 基因在乳腺癌中的表达情况和新辅助化疗对其的影响及临床意义。

方法

RT-PCR 检测56 例术前未行治疗的乳腺癌标本和36 例术前曾接受新辅助化疗的乳腺癌标本中ERCC1基因的表达。

结果

未化疗组的乳腺癌中,ERCC1 基因阳性表达率为37.5%,其表达水平与患者的年龄(t =0.229,P＞0.05)、肿瘤大小(F =0. 586,P＞0. 05)、淋巴结转移(t =0.365,P＞0.05)、病理分型(t =0.434,P＞0.05)、组织学分级(F=0.820,P＞0.05)、ER(t =0.523,P＞0.05)、PR(t =0.416,P＞0.05)和HER-2(t =0.847,P＞0.05)均无明显相关性。 新辅助化疗组ERCC1 基因的表达水平高于未化疗组,差异有统计学意义(t=3.428,P＜0.01)。

结论

耐药基因ERCC1 的表达不受乳腺癌临床病理特征的影响,但新辅助化疗可能上调ERCC1 基因的表达水平,在术后化疗中应予重视。

Objective

To investigate the expression and clinical significance of ERCC1 gene, one member of the nucleotide excision repair gene family, in breast cancer before and after neoadjuvant chemotherapy.

Methods

The expression of ERCC1 gene was detected by reverse transcription polymerase chain reaction (RT-PCR)in 56 specimens of breast cancer patients without any preoperative treatment and 36 tumor tissues of the patients who had been treated by neoadjuvant chemotherapy preoperatively.

Results

The positive expression rate of ERCC1 gene in breast cancer was 37.5%, and its expression had no relations with patient's age (t=0.229,P＞0.05),tumor size (F =0.586,P＞0.05), axillary lymph node metastasis (t =0.365,P＞0.05), pathological type (t=0.434,P＞0.05), histological grade (F =0.820,P＞0.05), ER(t=0.523,P＞0.05), PR (t =0.416,P＞0.05), and HER-2 (t =0.847,P＞0.05). The expression of ERCC1 gene in tumer was higher in neoadjuvant chemotherapy group than in the non-chemotherapy group, and there was a statistically significant difference (t=3.428,P＜0.01).

Conclusions

The expression of ERCC1 gene is not affected by the clinical and pathological features of breast cancer,but may be increased by neoadjuvant chemotherapy, so postoperative neoadjuvant chemotherapy should be given much attention.